Literature DB >> 15047202

HLA-Ig-based artificial antigen-presenting cells: setting the terms of engagement.

Mathias Oelke1, Jonathan P Schneck.   

Abstract

Recent advances in molecular medicine have shown that soluble MHC-multimers can be valuable tools for both the stimulation of as well as the analysis of antigen-specific T cells in vitro. In this review, we describe the use of dimeric major histocompatibility complexes, HLA-Ig, to visualize antigen-specific T cells as well as their potential to stimulate immune responses as part of an artificial antigen-presenting cell (aAPC). The use of HLA-Ig-based aAPC represents an exciting new approach to generate antigen-specific CTL for adoptive immunotherapy that helps to overcome many of the obstacles associated with limitations in current approaches to adoptive immunotherapy.

Mesh：

Substances：

Year:  2004        PMID： 15047202     DOI： 10.1016/j.clim.2003.11.014

Source DB:  PubMed          Journal:  Clin Immunol        ISSN： 1521-6616            Impact factor:   3.969


  8 in total

1.  A panel of artificial APCs expressing prevalent HLA alleles permits generation of cytotoxic T cells specific for both dominant and subdominant viral epitopes for adoptive therapy.

Authors:  Aisha N Hasan; Wouter J Kollen; Deepa Trivedi; Annamalai Selvakumar; Bo Dupont; Michel Sadelain; Richard J O'Reilly
Journal:  J Immunol       Date:  2009-07-27       Impact factor: 5.422

2.  A reproducible method for the enumeration of functional (cytokine producing) versus non-functional peptide-specific cytotoxic T lymphocytes in human peripheral blood.

Authors:  S N Markovic; W K Nevala; C B Uhl; E Celis; D J McKean
Journal:  Clin Exp Immunol       Date:  2006-09       Impact factor: 4.330

3.  CD47 Enhances In Vivo Functionality of Artificial Antigen-Presenting Cells.

Authors:  Heiko Bruns; Catherine Bessell; Juan Carlos Varela; Carl Haupt; Jerry Fang; Shirin Pasemann; Andreas Mackensen; Mathias Oelke; Jonathan P Schneck; Christian Schütz
Journal:  Clin Cancer Res       Date:  2015-01-15       Impact factor: 12.531

Review 4.  Induction/engineering, detection, selection, and expansion of clinical-grade human antigen-specific CD8 cytotoxic T cell clones for adoptive immunotherapy.

Authors:  Matjaz Jeras; Irena Bricl; Robert Zorec; Urban Svajger
Journal:  J Biomed Biotechnol       Date:  2010-03-10

5.  In vivo administration of artificial antigen-presenting cells activates low-avidity T cells for treatment of cancer.

Authors:  Stefano Ugel; Alessia Zoso; Carmela De Santo; Yu Li; Ilaria Marigo; Paola Zanovello; Elisa Scarselli; Barbara Cipriani; Mathias Oelke; Jonathan P Schneck; Vincenzo Bronte
Journal:  Cancer Res       Date:  2009-12-15       Impact factor: 12.701

6.  The Basics of Artificial Antigen Presenting Cells in T Cell-Based Cancer Immunotherapies.

Authors:  Lillian R Neal; Stefanie R Bailey; Megan M Wyatt; Jacob S Bowers; Kinga Majchrzak; Michelle H Nelson; Carl Haupt; Chrystal M Paulos; Juan C Varela
Journal:  J Immunol Res Ther       Date:  2017-06-26

7.  Separating T Cell Targeting Components onto Magnetically Clustered Nanoparticles Boosts Activation.

Authors:  Alyssa K Kosmides; Kevin Necochea; John W Hickey; Jonathan P Schneck
Journal:  Nano Lett       Date:  2018-02-28       Impact factor: 11.189

8.  T-cell memory responses elicited by yellow fever vaccine are targeted to overlapping epitopes containing multiple HLA-I and -II binding motifs.

Authors:  Andréa Barbosa de Melo; Eduardo J M Nascimento; Ulisses Braga-Neto; Rafael Dhalia; Ana Maria Silva; Mathias Oelke; Jonathan P Schneck; John Sidney; Alessandro Sette; Silvia M L Montenegro; Ernesto T A Marques
Journal:  PLoS Negl Trop Dis       Date:  2013-01-31
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.